Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial

Journal of Headache and Pain

Volumn 15, Issue 1, 2014, Pages

  Zhang, Haifeng ^a   Lian, Yajun ^a   Ma, Yunqing ^a   Chen, Yuan ^a   He, Caihong ^a   Xie, Nanchang ^a   Wu, Chuanjie ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Botulinum toxin type A; Double blind; Placebo controlled treatment; Trigeminal neuralgia

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ADULT; ARTICLE; ASSESSMENT OF HUMANS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FACE ASYMMETRY; FACE DISORDER; FEMALE; FOLLOW UP; HUMAN; INJECTION SITE EDEMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PAIN SEVERITY; PATIENT GLOBAL IMPRESSION OF CHANGE; RANDOMIZED CONTROLLED TRIAL; SUBMUCOSAL DRUG ADMINISTRATION; TREATMENT DURATION; TREATMENT RESPONSE; TRIGEMINUS NEURALGIA; VISUAL ANALOG SCALE; AGED; MIDDLE AGED; PAIN MEASUREMENT; TREATMENT OUTCOME; TRIGEMINAL NEURALGIA;

AGED; BOTULINUM TOXINS, TYPE A; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PAIN MEASUREMENT; TREATMENT OUTCOME; TRIGEMINAL NEURALGIA;

EID: 84919926818     PISSN: 11292369     EISSN: 11292377     Source Type: Journal    
DOI: 10.1186/1129-2377-15-65     Document Type: Article

References (28)

1. Headache Classification Subcommittee of the International Headache Society: The International Classification of Headache Disorders: 2nd edition.Cephalalgia 2004,24(suppl 1):9–160.
2. Campos WK, Linhares MN: A prospective study of 39 patients with trigeminal neuralgia treated with percutaneous balloon compression.Arq Neuropsiquiatr 2011, 69:221–226. 10.1590/S0004-282X2011000200016
3. Turp JC, Gobetti JP: Trigeminal neuralgia--an update.Compend Contin Educ Dent 2000, 21:279–282. 284, 287–8 passim;quiz 292
4. Zakrzewska JM, McMillan R: Trigeminal neuralgia: the diagnosis and management of this excruciating and poorly understood facial pain.Postgrad Med J 2011, 87:410–416. 10.1136/pgmj.2009.080473
5. Bendtsen L, Birk S, Kasch H, Aegidius K, Sorensen PS, Thomsen LL, Poulsen L, Rasmussen MJ, Kruuse C, Jensen R, Danish Headache Society: Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 2nd Edition.J Headache Pain 2012,13(Suppl 1):S1-S29.
6. Wu CJ, Lian YJ, Zheng YK: Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial.Cephalalgia 2012, 32:443–450. 10.1177/0333102412441721
7. Wu CJ, Shen JH, Chen Y, Lian YJ: Comparison of two different formulations of botulinum toxin A for the treatment of blepharospasm and hemifacial spasm.Turk Neurosurg 2011, 21:625–629.
8. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB: OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.Cephalalgia 2010, 30:793–803. 10.1177/0333102410364676
9. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB: OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.Cephalalgia 2010, 30:804–814. 10.1177/0333102410364677
10. Schoenen J: Botulinum toxin in headache treatment: finally a promising path.Cephalalgia 2010, 30:771–773. 10.1177/0333102410373154
11. Torgovnick J: OnabotulinumtoxinA for the treatment of chronic migraine not quite there.Cephalalgia 2011, 31:377. author reply 378–9 10.1177/0333102410388529
12. Allam N, Brasil-Neto JP, Brown G, Tomaz C: Injections of botulinum toxin type a produce pain alleviation in intractable trigeminal neuralgia.Clin J Pain 2005, 21:182–184. 10.1097/00002508-200503000-00010
13. Shen JH, Lian YJ, Zheng YK: Effect of botulinum toxin type a on clssic trigeminal neuralgia.Chin J Rehab Med 2011, 26:483–484.
14. Micheli F, Scorticati MC, Raina G: Beneficial effects of botulinum toxin type a for patients with painful tic convulsif.Clin Neuropharmacol 2002, 25:260–262. 10.1097/00002826-200209000-00006
15. Ngeow WC, Nair R: Injection of botulinum toxin type A (BOTOX) into trigger zone of trigeminal neuralgia as a means to control pain.Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010, 109:e47-e50.
16. Piovesan EJ, Leite LS, Teive HG, Kowacs PA, Mulinari RA, Radunz V: Botulinum toxin type-A effect as a preemptive treatment in a model of acute trigeminal pain: a pre-clinical double-blind and placebo-controlled study.Arq Neuropsiquiatr 2011, 69:56–63. 10.1590/S0004-282X2011000100012
17. Piovesan EJ, Teive HG, Kowacs PA, Della CMV, Werneck LC, Silberstein SD: An open study of botulinum-A toxin treatment of trigeminal neuralgia.Neurology 2005, 65:1306–1308. 10.1212/01.wnl.0000180940.98815.74
18. Turk U, Ilhan S, Alp R, Sur H: Botulinum toxin and intractable trigeminal neuralgia.Clin Neuropharmacol 2005, 28:161–162. 10.1097/01.wnf.0000172497.24770.b0
19. Zuniga C, Diaz S, Piedimonte F, Micheli F: Beneficial effects of botulinum toxin type A in trigeminal neuralgia.Arq Neuropsiquiatr 2008, 66:500–503. 10.1590/S0004-282X2008000400012
20. Olesen J, Steiner TJ: The International classification of headache disorders, 2nd edn (ICDH-II).J Neurol Neurosurg Psychiatry 2004, 75:808–811. 10.1136/jnnp.2003.031286
21. Borodic GE, Acquadro MA: The use of botulinum toxin for the treatment of chronic facial pain.J Pain 2002, 3:21–27. 10.1054/jpai.2002.27142
22. Bohluli B, Motamedi MH, Bagheri SC, Bayat M, Lassemi E, Navi F: Use of botulinum toxin A for drug-refractory trigeminal neuralgia: preliminary report.Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011, 111:47–50. 10.1016/j.tripleo.2010.04.043
23. Aoki KR: Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A.Neurotoxicology 2005, 26:785–793. 10.1016/j.neuro.2005.01.017
24. Ishikawa H, Mitsui Y, Yoshitomi T, Mashimo K, Aoki S, Mukuno K: Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles.Jpn J Ophthalmol 2000, 44:106–109. 10.1016/S0021-5155(99)00197-5
25. Meng J, Ovsepian SV, Wang J, Pickering M, Sasse A, Aoki KR: Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum boxin with anti-nociceptive potential.J Neurosic 2009, 29:4981–4992. 10.1523/JNEUROSCI.5490-08.2009
26. Woolf CJ, Costigan M: Transcriptional and posttranslational plasticity and the generation of inflammatory pain.Proc Natl Acad Sci 1999, 96:7723–7730. 10.1073/pnas.96.14.7723
27. Guyer BM: Mechanism of botulinum toxin in the relief of chronic pain.Curr Rev Pain 1999, 3:427–431. 10.1007/s11916-999-0069-y
28. Binder WJ, Brin MF, Blitzer A: Botulinum toxin type A (BOTOX) for treatment of migraine.Dis Mon 2002, 48:323–335. 10.1053/mda.2002.24423